Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.

Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium

Open access

Abstract

The Dementia with Lewy Bodies (DLB) Consortium has refined its recommendations about the clinical and pathologic diagnosis of DLB, updating the previous report, which has been in widespread use for the last decade. The revised DLB consensus criteria now distinguish clearly between clinical features and diagnostic biomarkers, and give guidance about optimal methods to establish and interpret these. Substantial new information has been incorporated about previously reported aspects of DLB, with increased diagnostic weighting given to REM sleep behavior disorder and 123iodine-metaiodobenzylguanidine (MIBG) myocardial scintigraphy. The diagnostic role of other neuroimaging, electrophysiologic, and laboratory investigations is also described. Minor modifications to pathologic methods and criteria are recommended to take account of Alzheimer disease neuropathologic change, to add previously omitted Lewy-related pathology categories, and to include assessments for substantia nigra neuronal loss. Recommendations about clinical management are largely based upon expert opinion since randomized controlled trials in DLB are few. Substantial progress has been made since the previous report in the detection and recognition of DLB as a common and important clinical disorder. During that period it has been incorporated into DSM-5, as major neurocognitive disorder with Lewy bodies. There remains a pressing need to understand the underlying neurobiology and pathophysiology of DLB, to develop and deliver clinical trials with both symptomatic and disease-modifying agents, and to help patients and carers worldwide to inform themselves about the disease, its prognosis, best available treatments, ongoing research, and how to get adequate support.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000004058

Cites

150 of 150 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Coronal T1-weighted MRI and 123iodine FP-CIT SPECT images in Alzheimer disease (AD), dementia with Lewy bodies (DLB), and normal controls (NC) (A) On the MRI, note the relative preservation of medial temporal lobe volume (rectangles) in DLB, which is similar to NC, whereas atrophy is obvious in AD. (B) On the FP-CIT SPECT images, note the minimal uptake in DLB, which is restricted to the caudate (period or full-stop appearance) compared to the robust uptake in the caudate and putamen in AD and NC (comma appearance). Reproduced with permission from Dr. Val Lowe, Mayo Clinic, Rochester, MN.
Figure 1 Coronal T1-weighted MRI and 123iodine FP-CIT SPECT images in Alzheimer disease (AD), dementia with Lewy bodies (DLB), and normal controls (NC) (A) On the MRI, note the relative preservation of medial temporal lobe volume (rectangles) in DLB, which is similar to NC, whereas atrophy is obvious in AD. (B) On the FP-CIT SPECT images, note the minimal uptake in DLB, which is restricted to the caudate (period or full-stop appearance) compared to the robust uptake in the caudate and putamen in AD and NC (comma appearance). Reproduced with permission from Dr. Val Lowe, Mayo Clinic, Rochester, MN.CC BY · PubMed Central
Figure 2 123Iodine-metaiodobenzylguanidine myocardial imaging in patients with Alzheimer disease (AD), dementia with Lewy bodies (DLB), and age-matched normal controls (NC) Images taken 3 hours after injection are shown in 2 color scales, and typical regions of interest are shown on the heart (dotted circle) and upper mediastinum (rectangle). Heart-to-mediastinum (H/M) ratios are standardized to the values comparable to a medium-energy general-purpose collimator condition.e12 Reproduced with permission from Dr. Kenichi Nakajima, Department of Nuclear Medicine, Kanazawa University.
Figure 2 123Iodine-metaiodobenzylguanidine myocardial imaging in patients with Alzheimer disease (AD), dementia with Lewy bodies (DLB), and age-matched normal controls (NC) Images taken 3 hours after injection are shown in 2 color scales, and typical regions of interest are shown on the heart (dotted circle) and upper mediastinum (rectangle). Heart-to-mediastinum (H/M) ratios are standardized to the values comparable to a medium-energy general-purpose collimator condition.e12 Reproduced with permission from Dr. Kenichi Nakajima, Department of Nuclear Medicine, Kanazawa University.CC BY · PubMed Central
Figure 3 Polysomnographic (PSG) recordings PSG recordings of normal REM sleep (A) and REM sleep without atonia, typical of REM sleep behavior disorder (B).REM are reflected by the high-amplitude, abrupt deviations from baseline in the electro-oculogram (EOG) leads during a 30-second epoch. In (A), note the absence of EMG activity in the submental, leg, and arm leads (green arrows), whereas increased EMG tone is present in the same leads (red arrows) in B, particularly in the middle (arm lead), in this patient.
Figure 3 Polysomnographic (PSG) recordings PSG recordings of normal REM sleep (A) and REM sleep without atonia, typical of REM sleep behavior disorder (B).REM are reflected by the high-amplitude, abrupt deviations from baseline in the electro-oculogram (EOG) leads during a 30-second epoch. In (A), note the absence of EMG activity in the submental, leg, and arm leads (green arrows), whereas increased EMG tone is present in the same leads (red arrows) in B, particularly in the middle (arm lead), in this patient.CC BY · PubMed Central
Figure 4 18F-FDG-PET images in Alzheimer disease (AD), dementia with Lewy bodies (DLB), and normal controls (NC) (A) Right lateral metabolic surface map projection. (B) Standard axial view transecting the posterior cingulate region. Occipital lobe metabolism is preserved in AD and NC but reduced (blue arrows) in DLB. Hypometabolism in AD is predominantly in the temporal, parietal, and frontal regions. There is normal metabolism as reflected by the normal 18F-FDG uptake (lighter shade of gray) in the posterior cingulate region (yellow arrowhead) surrounded by reduced 18F-FDG uptake (darker gray) in the adjacent occipital cortex in DLB, representing the cingulate island sign. This contrasts with the relatively reduced 18F-FDG uptake in the posterior cingulate and relatively preserved 18F-FDG uptake in the occipital cortex regions in AD. In the control, there is normal 18F-FDG uptake in the posterior cingulate, occipital, and other neocortical regions. Color and grayscale sidebars show increasing degrees of deviation from normal as the signal trends lower in the sidebars (red is normal while black is maximally abnormal in color images; white is normal while black is maximally abnormal in grayscale images). Reproduced with permission from Dr. Val Lowe, Mayo Clinic, Rochester, MN.
Figure 4 18F-FDG-PET images in Alzheimer disease (AD), dementia with Lewy bodies (DLB), and normal controls (NC) (A) Right lateral metabolic surface map projection. (B) Standard axial view transecting the posterior cingulate region. Occipital lobe metabolism is preserved in AD and NC but reduced (blue arrows) in DLB. Hypometabolism in AD is predominantly in the temporal, parietal, and frontal regions. There is normal metabolism as reflected by the normal 18F-FDG uptake (lighter shade of gray) in the posterior cingulate region (yellow arrowhead) surrounded by reduced 18F-FDG uptake (darker gray) in the adjacent occipital cortex in DLB, representing the cingulate island sign. This contrasts with the relatively reduced 18F-FDG uptake in the posterior cingulate and relatively preserved 18F-FDG uptake in the occipital cortex regions in AD. In the control, there is normal 18F-FDG uptake in the posterior cingulate, occipital, and other neocortical regions. Color and grayscale sidebars show increasing degrees of deviation from normal as the signal trends lower in the sidebars (red is normal while black is maximally abnormal in color images; white is normal while black is maximally abnormal in grayscale images). Reproduced with permission from Dr. Val Lowe, Mayo Clinic, Rochester, MN.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

8 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 146 references

Cited by

See all 4,476

Metadata

Authors
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., Bayston, A., Beach, T. G., Blanc, F., Bohnen, N., Bonanni, L., Bras, J., Brundin, P., Burn, D., Chen-Plotkin, A., Duda, J. E., El-Agnaf, O., Feldman, H., Ferman, T. J., ffytche, D., Fujishiro, H., Galasko, D., Goldman, J. G., Gomperts, S. N., Graff-Radford, N. R., Honig, L. S., Iranzo, A., Kantarci, K., Kaufer, D., Kukull, W., Lee, V. M. Y., Leverenz, J. B., Lewis, S., Lippa, C., Lunde, A., Masellis, M., Masliah, E., McLean, P., Mollenhauer, B., Montine, T. J., Moreno, E., Mori, E., Murray, M., O'Brien, J. T., Orimo, S., Postuma, R. B., Ramaswamy, S., Ross, O. A., Salmon, D. P., Singleton, A., Taylor, A., Thomas, A., Tiraboschi, P., Toledo, J. B., Trojanowski, J. Q., Tsuang, D., Walker, Z., Yamada, M., & Kosaka, K.
Affiliations
Author affiliations are provided at the end of the article.
Corresponding author
McKeith, Ian G.
Venue
Neurology
Published
2017-07-04
Volume
89
Issue
1
Pages
88-100
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2623521763
Cited by
4,476
References
146
Citations by year
2026: 453 · 2025: 619 · 2024: 546 · 2023: 469 · 2022: 558 · 2021: 500 · 2020: 491 · 2019: 371 · 2018: 244 · 2017: 43
FWCI
218.92
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Neurology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • eScholarship@McGill (McGill) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • Research Portal (King's College London) (submittedVersion, cc-by)
  • GRO (submittedVersion)
  • Newcastle University ePrints (Newcastle Univesity) (cc-by)
Funders
  • U.S. Department of Health and Human Services
  • U.S. Department of Veterans Affairs
  • California Institute for Regenerative Medicine
  • Bristol-Myers Squibb
  • Alzheimer's Drug Discovery Foundation
  • Eli Lilly and Company
  • Pfizer
  • GlaxoSmithKline
  • Sanofi
  • Heart and Stroke Foundation of Canada
  • Massachusetts General Hospital
  • Van Andel Research Institute
  • Biogen
  • CHDI Foundation
  • Teva Pharmaceutical Industries
  • Florida Department of Health
  • University of Pennsylvania
  • Cleveland Clinic
  • University of Washington
  • International Parkinson and Movement Disorder Society
  • Thomas Jefferson University
  • CurePSP
  • Rush University
  • Florida Atlantic University
  • Fondation Brain Canada
  • Little Family Foundation
  • Demensförbundet
  • Weston Brain Institute
  • ACADIA Pharmaceuticals
  • Houston Methodist Hospital
  • Universidad del Atlántico
  • Kanazawa University
  • Sunnybrook Foundation
  • TauRx Pharmaceuticals
  • National Institute for Health and Care Research (RP-PG-0610-10100, NF-SI-0611-10048)
  • University of Exeter
  • King's College London
  • University College London
  • University of Oxford
  • Newcastle University
  • Bundesministerium für Bildung und Forschung
  • Ministero della Salute
  • University of Toronto
  • Université de Strasbourg
  • Eisai
  • Newcastle upon Tyne Hospitals NHS Foundation Trust
  • Centre National de la Recherche Scientifique
  • Ministero dello Sviluppo Economico
  • Stifterverband
  • H. Lundbeck A/S
  • Deutsche Parkinson Vereinigung
  • National Institutes of Health
  • Genentech
  • University of North Carolina at Chapel Hill
  • University of California, San Diego
  • Perelman School of Medicine, University of Pennsylvania
  • Avid Radiopharmaceuticals
  • Houston Methodist Research Institute
  • Qatar Biomedical Research Institute, Hamad Bin Khalifa University
  • Canadian Institutes of Health Research
  • Medical Research Council (MR/L016451/1)
  • National Health and Medical Research Council
  • Programme Grants for Applied Research
  • NIHR Newcastle Biomedical Research Centre
  • National Institute on Aging (U01AG016976, P50AG005131, P01AG003949, P30AG010124, P50AG005136, P50AG016574)
  • National Institute of Neurological Disorders and Stroke (R01NS078086, P50NS053488, P50NS091856, U01NS082134, R13NS095618, R01NS082265, P50NS072187, U01NS097056)
  • National Institute for Dementia Research
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
Keywords
dementia with Lewy bodies, diagnosis, diagnostic biomarkers, REM sleep behavior disorder, MIBG myocardial scintigraphy, Lewy bodies, disease management, caregiver support
MeSH terms
Humans, Biomarkers, Practice Guidelines as Topic, Lewy Body Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. https://app.cochat.ai/papers/10.1212/wnl.0000000000004058
The paper
McKeith, I. G., Boeve, B. F., Dickson, D. W., Halliday, G., Taylor, J.-P., Weintraub, D., Aarsland, D., Galvin, J., Attems, J., Ballard, C. G., Bayston, A., Beach, T. G., Blanc, F., Bohnen, N., Bonanni, L., Bras, J., Brundin, P., Burn, D., Chen-Plotkin, A., . . . Kosaka, K. (2017). Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. https://doi.org/10.1212/wnl.0000000000004058

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.